Kennedy's new CDC panel includes members who have criticized vaccines and spread misinformation
NEW YORK (AP) — U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week.
They include a scientist who researched mRNA vaccine technology and became a conservative darling for his criticisms of COVID-19 vaccines, a leading critic of pandemic-era lockdowns, and a professor of operations management.
Kennedy's decision to 'retire' the previous 17-member Advisory Committee on Immunization Practices was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations.
On Tuesday, before he announced his picks, Kennedy said: 'We're going to bring great people onto the ACIP panel – not anti-vaxxers – bringing people on who are credentialed scientists.'
The new appointees include Vicky Pebsworth, a regional director for the National Association of Catholic Nurses. She has been listed as a board member and volunteer director for the National Vaccine Information Center, a group that is widely considered to be a leading source of vaccine misinformation.
Another is Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to prominence during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19.
He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots and has suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years.
Malone told The Associated Press he will do his best 'to serve with unbiased objectivity and rigor.'
Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named.
Abram Wagner of the University of Michigan's school of public health, who investigates vaccination programs, said he's not satisfied with the composition of the committee.
'The previous ACIP was made up of technical experts who have spent their lives studying vaccines,' he said. Most people on the current list 'don't have the technical capacity that we would expect out of people who would have to make really complicated decisions involving interpreting complicated scientific data.'
He said having Pebsworth on the board is 'incredibly problematic' since she is involved in an organization that 'distributes a lot of misinformation.'
Kennedy made the announcement in a social media post on Wednesday.
The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how vaccines that have been approved by the Food and Drug Administration should be used. The CDC's final recommendations are widely heeded by doctors and guide vaccination programs.
The other appointees are:
—Dr. James Hibbeln, who formerly headed a National Institutes of Health group focused on nutritional neurosciences and who studies how nutrition affects the brain, including the potential benefits of seafood consumption during pregnancy.
—Retsef Levi, a professor of operations management at the Massachusetts Institute of Technology who studies business issues related to supply chain, logistics, pricing optimization and health and health care management. In a 2023 video pinned to an X profile under his name, Levi called for the end of the COVID-19 vaccination program, claiming the vaccines were ineffective and dangerous despite evidence they saved millions of lives. Levi told the AP he would try to help inform 'public health policies with data and science, with the goal of improving the health and wellbeing of people and regain the public trust.'
—Dr. James Pagano, an emergency medicine physician from Los Angeles.
—Dr. Michael Ross, a Virginia-based obstetrician and gynecologist who previously served on a CDC breast and cervical cancer advisory committee. He is described as a 'serial CEO and physician leader' in a bio for Havencrest Capital Management, a private equity investment firm where he is an operating partner.
Of the eight named by Kennedy, perhaps the most experienced in vaccine policy is Meissner, an expert in pediatric infectious diseases at Dartmouth-Hitchcock Medical Center, who has previously served as a member of both ACIP and the Food and Drug Administration's vaccine advisory panel.
During his five-year term as an FDA adviser, the committee was repeatedly asked to review and vote on the safety and effectiveness of COVID-19 vaccines that were rapidly developed to fight the pandemic. In September 2021, he joined the majority of panelists who voted against a plan from the Biden administration to offer an extra vaccine dose to all American adults. The panel instead recommended that the extra shot should be limited to seniors and those at higher risk of the disease.
Ultimately, the FDA disregarded the panel's recommendation and OK'd an extra vaccine dose for all adults.
In addition to serving on government panels, Meissner has helped author policy statements and vaccination schedules for the American Academy of Pediatrics.
ACIP members typically serve in staggered four-year terms, although several appointments were delayed during the Biden administration before positions were filled last year. The voting members are all supposed to have scientific or clinical expertise in immunization, except for one 'consumer representative' who can bring perspective on community and social facets of vaccine programs.
Kennedy, a leading voice in the anti-vaccine movement before becoming the U.S. government's top health official, has accused the committee of being too closely aligned with vaccine manufacturers and of rubber-stamping vaccines. ACIP policies require members to state past collaborations with vaccine companies and to recuse themselves from votes in which they had a conflict of interest, but Kennedy has dismissed those safeguards as weak.
Most of the people who best understand vaccines are those who have researched them, which usually requires some degree of collaboration with the companies that develop and sell them, said Jason Schwartz, a Yale University health policy researcher.
'If you are to exclude any reputable, respected vaccine expert who has ever engaged even in a limited way with the vaccine industry, you're likely to have a very small pool of folks to draw from,' Schwartz said.
The U.S. Senate confirmed Kennedy in February after he promised he would not change the vaccination schedule. But less than a week later, he vowed to investigate childhood vaccines that prevent measles, polio and other dangerous diseases.
Kennedy has ignored some of the recommendations ACIP voted for in April, including the endorsement of a new combination shot that protects against five strains of meningococcal bacteria and the expansion of vaccinations against RSV.
In late May, Kennedy disregarded the committee and announced the government would change the recommendation for children and pregnant women to get COVID-19 shots.
On Monday, Kennedy ousted all 17 members of the ACIP, saying he would appoint a new group before the next scheduled meeting in late June. The agenda for that meeting has not yet been posted, but a recent federal notice said votes are expected on vaccinations against flu, COVID-19, HPV, RSV and meningococcal bacteria.
A HHS spokesman did not respond to a question about whether there would be only eight ACIP members, or whether more will be named later.
___
Associated Press reporters Matthew Perrone, Amanda Seitz, Devi Shastri and Laura Ungar contributed to this report.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Vogue Arabia
a day ago
- Vogue Arabia
10 Foods That Naturally Lower Cortisol Levels
If you spend a lot of time on TikTok, then you'll be familiar with the phrase 'cortisol face'. Characterised by puffiness and swelling of the face and neck, cortisol face has become a much bandied-about term. Cortisol – known as the 'stress hormone' – is produced by the adrenal glands as a response to stressful or dangerous situations. Essential for our survival, it regulates immune response, blood sugar and blood pressure. In excess, though, it can affect our lymphatic system and cause puffiness in the eyes, cheeks and jaw. While scientific research into the concept of cortisol face is lacking, anecdotal evidence abounds. However, experts are keen to stress that signs of 'cortisol face' could actually be related to taking steroids, or to Cushing's syndrome – a (very) rare condition that occurs when the body produces too much cortisol. Too much cortisol for too long is not good for anyone's health. In ideal circumstances, the body naturally lowers cortisol levels when the stress or 'threat' has passed, but if stress persists for a long time, high cortisol levels can keep the body in a 'fight or flight' state. This can inhibit the immune system and alter the gut microbiome, making us vulnerable to inflammation and infection, as well as potentially causing fatigue, irritability, headaches, brain fog, acne, insomnia, weight gain and even anxiety and depression. Mitigating all of the stress in our lives is largely impossible. However, there are ways to manage it – be that through mindfulness, meditation, pranayama, yoga, moderate exercise or just regular, good-quality sleep. Similarly, a healthy, balanced diet that's low in refined sugars, saturated fats, excess alcohol and caffeine – all things that can raise cortisol – but rich in adequate omega-3, magnesium, fibre and antioxidants, can help counteract cortisol. Here are the best foods to include in your diet if tackling stress is your main concern. 1. Leafy greens Leafy green vegetables such as spinach, arugula and kale are chock-full of vitamins, minerals and antioxidants. They are also rich in folate, which can help to regulate cortisol levels and promote a healthy gut microbiome, essential for the production of neurotransmitters such as serotonin, another cortisol mitigator. 2. Bitter chocolate It's not news that small amounts of dark chocolate – containing at least 70% cocoa – is good for you. Rich in antioxidants, it's healthier than milk or white alternatives. Less well known is the fact that the flavonoids in cocoa can help mitigate the stress response from the adrenal glands and the subsequent release of cortisol. Plus, chocolate can help put you in a better mood. 3. Green tea Rich in catechins, a category of antioxidant polyphenols, and L-theanine, an amino acid that promotes relaxation, green tea is soothing and energising at the same time, and the ideal drink to sip when you're stressed out. Consume it in loose leaf, tea bag or matcha form. It can also be added to smoothies and desserts. 4. Salmon Perhaps the ultimate skin-friendly food, salmon (like other types of fish rich in healthy fats, like sardines and mackerel), can help regulate cortisol levels, thanks to its anti-inflammatory omega-3 content. In fact, some studies have found that fish oils can counteract adrenal gland activation in stressful situations. 5. Avocado Another skin-loving food, avocado contains significant amounts of potassium, as well as magnesium, an anti-stress mineral that promotes sleep and muscle relaxation by helping to counteract cortisol. Pair it with a boiled or poached egg on toast for a balanced breakfast. 6. Legumes Chickpeas, beans and fava beans, as well as lentils, peas and lupins, are all excellent sources of fibre that support gut health and regulate blood sugar. In addition, they are rich in B vitamins and magnesium, both of which contribute to the healthy function of the nervous system. 7. Berries Blackberries, blueberries, cranberries, raspberries and the like are tiny powerhouses of free radical-fighting antioxidants. Because of this, they reduce oxidative stress and cortisol levels. Add berries to smoothies and yoghurt, or eat them with a handful of almonds and walnuts. 8. Nuts Almonds, walnuts, hazelnuts, cashews, and Brazil nuts all have anti-stress properties, thanks to their combination of good fats, magnesium, B vitamins, and antioxidants. Add them to salads and pasta dishes, or keep a stash handy to snack on between meals. 9. Eggs In addition to being an outstanding source of quality protein, vitamins and minerals, eggs contain choline, an essential nutrient that plays a vital role in brain health, and helps to reduce stress and anxiety by improving emotional wellbeing. Eating a protein-rich, egg-based breakfast in the morning can be an easy way to stay full and satisfied until lunch. 10. Chia seeds Rich in anti-inflammatory omega-3s, chia seeds help to lower cortisol levels and promote a sense of calm. Make chia seed pudding with dairy or non-dairy milk, add them to smoothies, or create an easy chocolate mousse by soaking them in almond milk and then blending them with pure cocoa, with a teaspoon of maple syrup or honey for added sweetness. Article originally published on Vogue Italy


Globe and Mail
2 days ago
- Globe and Mail
NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Companies and 10+ Therapies
DelveInsight's, 'Non-Small-Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the NSCLC Treatment Landscape. Click here to read more @ NSCLC Pipeline Outlook Key Takeaways from the NSCLC Pipeline Report In June 2025, Revolution Medicines Inc. announced a study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel. This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy. In June 2025, Amgen conducted a study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR). In June 2025, Allist Pharmaceuticals Inc. organized a Phase 3 clinical study to assess the efficacy and safety of adjuvant treatment with firmonertinib versus placebo in participants with Stage IB-IIIB NSCLC with uncommon EGFR mutations (exon 20 insertions, PACC and classical-like mutations) after complete surgical resection with or without adjuvant chemotherapy. In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC. DelveInsight's NSCLC pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for NSCLC treatment. The leading NSCLC Companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Promising NSCLC Pipeline Therapies such as Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. Stay informed about the cutting-edge advancements in NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ NSCLC Clinical Trials Assessment NSCLC Emerging Drugs Profile AMG 510: Amgen AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC. CMP 001: Cytos Biotechnology CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer. The NSCLC Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment. NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different NSCLC mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market Learn more about NSCLC Drugs opportunities in our groundbreaking NSCLC research and development projects @ NSCLC Unmet Needs NSCLC Companies GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Parenteral Intramuscular Molecule Type NSCLC Products have been categorized under various Molecule types such as Small molecules Peptides Polymer Gene Therapy Monoclonal antibodies Product Type Discover the latest advancements in NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ NSCLC Market Drivers and Barriers, and Future Perspectives Scope of the NSCLC Pipeline Report Coverage- Global NSCLC Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. NSCLC Pipeline Therapies- Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of NSCLC Pipeline on our website @ NSCLC Emerging Drugs and Companies Table of Contents Introduction Executive Summary Non-Small-Cell Lung cancer (NSCLC): Overview Pipeline Therapeutics Therapeutic Assessment Non-Small-Cell Lung cancer (NSCLC) – DelveInsight's Analytical Perspective In-depth Commercial Assessment Late Stage Products (Pre Registration) AMG 510: Amgen Drug profiles in the detailed report….. Mid Stage Products (Phase II) Drug Name: Company Name Drug profiles in the detailed report….. Early Stage Products (Phase I) CMP 001: Cytos Biotechnology Inactive Products Non-Small-Cell Lung cancer (NSCLC) Key Companies Non-Small-Cell Lung cancer (NSCLC) Key Products Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion Non-Small-Cell Lung cancer (NSCLC) Analyst Views Non-Small-Cell Lung cancer (NSCLC) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:


Health Line
2 days ago
- Health Line
Which Fruits Support Platelets Naturally?
Eating fruits high in vitamin C, folate, and iron may help support your platelet count. A low platelet count increases your risk of excessive bleeding. Platelets are the smallest of your blood cells. When a blood vessel is damaged, platelets gather and form clots to prevent bleeding. A low platelet count may occur when your bone marrow doesn't produce sufficient platelets, your body destroys or depletes them, or your spleen (which stores about one-third of your platelets) retains too many of them. Among the factors that may lead to a low platelet count are: blood-thinning medications pregnancy leukemia, lymphoma, or other blood cancers autoimmune diseases, including immune thrombocytopenia, rheumatoid arthritis, and lupus exposure to toxic chemicals like pesticides One way to help increase your platelet count naturally is by eating healthy foods, including the following fruits. However, some fruits have antiplatelet properties, meaning they help stop platelets from sticking to one another. This reduces blood's ability to form clots. Which fruits may increase platelets? The following fruits contain platelet-supporting vitamins and minerals such as vitamin C, folate, and iron. Oranges: Along with vitamin C, citrus fruits are rich in folate, or vitamin B9, which is essential for healthy blood cells. A large orange contains 55 micrograms (mcg) of folate, about 14% of the recommended daily value (DV) of 400 mcg for adults. Mangoes: Mangos are loaded with vitamin C, which is important for the function and grouping of your platelets. A 1-cup (165-gram) serving provides 66% of the recommended DV of 90 milligrams (mg) for vitamin C. Papaya: Just 1 cup (145 grams [g]) of this tropical fruit has nearly 98% of the DV for vitamin C. Also, a 2019 study suggests that papaya leaf extract significantly increased the platelet levels of children with dengue fever. Strawberries: The National Health Service (NHS) recommends strawberries as a good source of vitamin C. 3.5 ounces (100 g) of strawberries contain about 67% of the DV for adults. Prunes: Dried fruits like prunes, figs, and raisins contain significant amounts of iron, which research shows is necessary for your platelets to function efficiently. A serving of 100 g of prunes has more than 3.5 mg of iron, which is 19% of DV. Just be aware that dried fruits are also higher in sugar and calories. Cantaloupe: A 1-cup serving of this melon provides 19% of the DV of vitamin C. Cantaloupe also contains folate and iron, but not in significant amounts. Pumpkin: One cup of pumpkin provides just over 10% of the DV for vitamin C. But, a 2021 Chilean study found the seeds from the Cucurbita maxima variety have significant antiplatelet potential. Pomegranate: A 4-inch pomegranate provides 32% of the DV for vitamin C. There's evidence that these fruits have a positive influence on heart health, including platelet function. Which fruits decrease platelets? The following fruits have antiplatelet properties, such as the antioxidant quercetin. If your platelet count is low, you might want to eat those fruits in moderation or avoid them altogether. These antiplatelet properties are beneficial for people with high platelet counts, which is called thrombocythemia, or people at risk for a heart attack or stroke. Pineapple is a special case when it comes to your platelet count. A cup of pineapple provides 88% of the DV for vitamin C. However, pineapple also contains bromelain, an enzyme with antiplatelet properties. Ask a doctor or dietitian whether you should enjoy or avoid pineapple. Other ways to increase platelets naturally Besides eating certain fruits, the following foods are rich in vitamin B12, which is necessary for the formation of red blood cells and may help support your platelet count: These are some other foods that are natural sources of folate and iron: leafy green vegetables like spinach asparagus brussels sprouts peanuts kidney beans peas lean meat poultry Remember that dietary approaches should not replace medical treatment for serious platelet disorders. If your clotting issues are serious, consult a healthcare professional as soon as possible. What are the signs of a low platelet count? A healthy platelet count generally ranges from 150,000 to 450,000 platelets per microliter of blood. It varies depending on your age, sex, and race. Young people, women, and non-Hispanic Black people may have somewhat higher platelet counts. Your platelets can be measured in a complete blood count. A low platelet count, called thrombocytopenia, is when the platelet count is less than 150,000 platelets per microliter of blood and increases your risk of excessive bleeding. Some of the symptoms of a low platelet count include: